Selvita S.A. Stock Deutsche Boerse AG

Equities

787

PLSLVCR00029

Biotechnology & Medical Research

Market Closed - Deutsche Boerse AG 02:22:28 2024-05-31 EDT 5-day change 1st Jan Change
15.08 EUR -3.21% Intraday chart for Selvita S.A. -8.38% +11.21%

Financials

Sales 2024 * 392M 99.52M 92.03M 136M Sales 2025 * 479M 122M 113M 166M Capitalization 1.21B 308M 285M 420M
Net income 2024 * 18M 4.57M 4.23M 6.24M Net income 2025 * 43M 10.93M 10.11M 14.91M EV / Sales 2024 * 3.58 x
Net Debt 2024 * 191M 48.54M 44.89M 66.23M Net Debt 2025 * 221M 56.23M 52M 76.73M EV / Sales 2025 * 2.99 x
P/E ratio 2024 *
17.4 x
P/E ratio 2025 *
28.1 x
Employees 886
Yield 2024 *
-
Yield 2025 *
-
Free-Float 78.68%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.21%
1 week-8.38%
1 month-1.82%
3 months+13.73%
6 months+14.24%
Current year+11.21%
More quotes
1 week
15.08
Extreme 15.08
16.40
1 month
15.08
Extreme 15.08
16.46
Current year
12.84
Extreme 12.84
16.46
1 year
12.40
Extreme 12.4
17.04
3 years
12.36
Extreme 12.36
19.30
5 years
12.00
Extreme 12
19.30
10 years
12.00
Extreme 12
19.30
More quotes
Managers TitleAgeSince
Chief Executive Officer - 07-08-31
Director of Finance/CFO - 19-07-31
Chief Operating Officer - 09-01-01
Members of the board TitleAgeSince
Director/Board Member 47 19-09-18
Director/Board Member - 19-09-18
Director/Board Member 72 -
More insiders
Date Price Change
24-05-31 15.08 -3.21%
24-05-30 15.58 -.--%
24-05-29 15.58 -0.76%
24-05-28 15.7 -4.27%
24-05-27 16.4 -0.36%

Delayed Quote Deutsche Boerse AG, May 31, 2024 at 02:22 am

More quotes
Selvita SA, formerly Selvita Cro SA, is a Poland-based integrated service company active in the pharmaceutical and biotechnology industries. The Company is engaged in providing multidisciplinary solutions supporting customers and projects within area of drug discovery, regulatory studies, as well as research and development. It offers its clients drug discovery support at every stage of the early discovery phase up to preclinical research, from target validation up to the selection of a clinical candidate. Also, it offers services at every stage of the drug discovery process in the field of drug testing and bioanalytical analyses, from development and validation of methods, stability studies, to routine quality control testing. The Company cooperates with numerous research institutes and universities from Europe and the United States.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
66 PLN
Average target price
68.98 PLN
Spread / Average Target
+4.52%
Consensus

Quarterly revenue - Rate of surprise